Delivery Order 36F79718D0403-36C26024F0508
Award Date
7/20/24
Potential Completion Date
12/31/24
Potential Value
$74K
Federal Agency
Veterans Integrated Service Network 20
Awardee
Daiichi Sankyo, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Cary, NC 27513, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the pharmaceutical product pexidartinib (marketed as TURALIO) supplied by Daiichi Sankyo, Inc., a for-profit pharmaceutical manufacturer. The contract, valued at $112,289.73, is a delivery order placed through the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule (FSS-61-IB) and was awarded by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network 20. The contract has a performance period ending on September...
This is a delivery order contract awarded by the U.S. Department of Veterans Affairs (VA) to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products. The contract is for the supply of ICLUSIG 45 MG, a specialty oncology medication, to various VA medical facilities across the country. The contract has a ceiling value of $13,956.72 and is a firm-fixed-price delivery order placed against Takeda's General Services Administration (GSA) Schedule...
This is a firm-fixed-price delivery order awarded by the Department of Veterans Affairs' (VA) Veterans Integrated Service Network 20 to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The $27,913.44 order was placed against Takeda's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs and has an ultimate completion date of August 19, 2024. The order is for the delivery of emergency pharmaceutical products,...
This is a firm-fixed-price delivery order awarded by the U.S. Department of Veterans Affairs (VA) to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the supply of the oncology medication ICLUSIG 15 MG, and is issued under Takeda's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs. The contract has a ceiling value of $14,197.39 and a completion date of February 25, 2025. This delivery order is part...
The U.S. Department of Veterans Affairs (VA) awarded a $13,956.72 firm-fixed-price delivery order contract to Takeda Pharmaceuticals America, Inc. for the supply of ICLUSIG 15 MG, a specialty oncology medication. This order was placed against Takeda's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs and supports the VA's procurement of critical drugs for its nationwide network of medical facilities. The contract has an ultimate completion date of November 11,...
This is a $90,000.00 firm fixed-price delivery order awarded by the Federal Medical Center Devens, a civilian agency, to Takeda Pharmaceuticals America Inc. The contract is for the supply of specialized pharmaceutical products, including medications for rare diseases, hematology, immunology, oncology, and critical medical treatments. It is part of a larger $19,472,334.90 Blanket Purchase Agreement (BPA) that Takeda Pharmaceutical Company LIMITED, the parent company, holds with the Department...
The U.S. Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a $27,913.44 firm-fixed-price delivery order to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical products. The order is for the oncology medication ICLUSIG 15MG TABS under Takeda's existing General Services Administration (GSA) Multiple Award Schedule contract for Pharmaceuticals and Drugs. This delivery order is part of a larger $13 million single-award...
The Department of Veterans Affairs (VA) Veterans Health Administration (VHA) awarded a delivery order contract to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit manufacturer, to provide its ICLUSIG 15 MG oncology medication. The $13,956.72 firm-fixed-price contract is part of a larger Blanket Purchase Agreement (BPA) under Takeda's General Services Administration (GSA) Multiple Award Schedule contract for Pharmaceuticals and Drugs. This BPA enables the VA to procure the...
This is a firm-fixed-price delivery order contract awarded by the Department of Veterans Affairs (VA) to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit pharmaceutical manufacturer. The contract has a ceiling value of $69,783.60 and supports the delivery of the oncology medication ICLUSIG (ponatinib) to VA medical facilities nationwide through September 2024. The contract is issued under Takeda's existing General Services Administration (GSA) Schedule 61-IB for...
The U.S. Department of Veterans Affairs (VA) awarded a $55,826.88 firm-fixed-price delivery order contract to Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the oncology medication ICLUSIG (ponatinib). This contract is part of a $123.5 million Blanket Purchase Agreement (BPA) that Takeda holds with the VA National Acquisition Center, which allows various VA medical facilities to easily order specialized oncology drugs. The contract supports...